Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fortin

Showing results (131-140 of 329) with videos related to

Pageof 33
Sort By:
The Journal of Rheumatology|January 18, 2011
Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosusCarolina Landolt-Marticorena, Robert Wither, Heather Reich, et al.
Journal of Medicinal Chemistry|September 17, 1993
Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816J H Hutchinson, D Riendeau, C Brideau, et al.
Progress in Clinical and Biological Research|January 1, 1989
The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptorJ W Gillard, H E Morton, R Fortin, et al.
Canadian Journal of Physiology and Pharmacology|May 1, 1989
L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitorJ Gillard, A W Ford-Hutchinson, C Chan, et al.
Canadian Journal of Physiology and Pharmacology|December 1, 1986
L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonistT R Jones, Y Guindon, R Young, et al.
Arthritis and Rheumatism|April 1, 2006
Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosusPierre Chagnon, Rayfel Schneider, Josée Hébert, et al.
Annals of the Rheumatic Diseases|September 6, 2008
Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosusC Landolt-Marticorena, G Bonventi, A Lubovich, et al.
Frontiers in Immunology|June 17, 2022
Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus NephritisLaura Whittall-Garcia, Kirubel Goliad, Michael Kim, et al.
Lupus|May 6, 2003
Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studiesE W Karlson, L H Daltroy, C Rivest, et al.
The Journal of Rheumatology|June 3, 2010
Serum albumin as a marker for disease activity in patients with systemic lupus erythematosusJonathan Yip, Elaheh Aghdassi, Jiandong Su, et al.
Pageof 33

Showing results (131-140 of 329) with videos related to

Sort By:
Pageof 33
The Journal of Rheumatology|January 18, 2011
Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosusCarolina Landolt-Marticorena, Robert Wither, Heather Reich, et al.
Journal of Medicinal Chemistry|September 17, 1993
Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816J H Hutchinson, D Riendeau, C Brideau, et al.
Progress in Clinical and Biological Research|January 1, 1989
The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptorJ W Gillard, H E Morton, R Fortin, et al.
Canadian Journal of Physiology and Pharmacology|May 1, 1989
L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitorJ Gillard, A W Ford-Hutchinson, C Chan, et al.
Canadian Journal of Physiology and Pharmacology|December 1, 1986
L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonistT R Jones, Y Guindon, R Young, et al.
Arthritis and Rheumatism|April 1, 2006
Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosusPierre Chagnon, Rayfel Schneider, Josée Hébert, et al.
Annals of the Rheumatic Diseases|September 6, 2008
Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosusC Landolt-Marticorena, G Bonventi, A Lubovich, et al.
Frontiers in Immunology|June 17, 2022
Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus NephritisLaura Whittall-Garcia, Kirubel Goliad, Michael Kim, et al.
Lupus|May 6, 2003
Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studiesE W Karlson, L H Daltroy, C Rivest, et al.
The Journal of Rheumatology|June 3, 2010
Serum albumin as a marker for disease activity in patients with systemic lupus erythematosusJonathan Yip, Elaheh Aghdassi, Jiandong Su, et al.
Pageof 33